-0.90% were higher Thursday afternoon, even as shares of the pharmaceutical company dropped toward an eight-month low after a court ruling invalidated a patent on its multiple sclerosis treatment.That was just one quirk among many in the popular biotech ETF space, a subsector thatâ€™s outperformed other categories, like Health Care Equipment and Pharmaceuticals, according to research provider CFRA.